Paper20204473
Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling.
Jacqmin P and 2 others. J Pharmacokinet Pharmacodyn, 2010. Cited by 18 papers, by iCite.
Cite this record
ConductScience Library. Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling. Papers, record 20204473. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20204473
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Disease Progression | Major topic |
| Models, Biological | Major topic |
| Pharmacokinetics | Major topic |
| Pharmacology | Major topic |
| Antiviral Agents | |
| Humans | |
| Logistic Models | |
| Microbial Sensitivity Tests | |
| Viral Load | |
| Virus Diseases |
Source PubMed
References33
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16786410 | A non-linear mixed effect dynamic model incorporating prior exposure and adherence to treatment to describe long-term therapy outcome in HIV-patients. | J Pharmacokinet Pharmacodyn | 2006 | https://conductscience.org/library/papers/16786410 | PubMed |
| 2 | 11391158 | Quantification of in vivo replicative capacity of HIV-1 in different compartments of infected cells. | J Acquir Immune Defic Syndr | 2001 | https://conductscience.org/library/papers/11391158 | PubMed |
| 3 | 11362021 | Models of viral kinetics and drug resistance in HIV-1 infection. | AIDS Patient Care STDS | 1998 | https://conductscience.org/library/papers/11362021 | PubMed |
| 4 | 11714222 | What do we really know about antibiotic pharmacodynamics? | Pharmacotherapy | 2001 | https://conductscience.org/library/papers/11714222 | PubMed |
| 5 | 16625427 | Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments. | J Pharmacokinet Pharmacodyn | 2006 | https://conductscience.org/library/papers/16625427 | PubMed |
| 6 | 17522597 | Model-based drug development. | Clin Pharmacol Ther | 2007 | https://conductscience.org/library/papers/17522597 | PubMed |
| 7 | 17067280 | Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. | Annu Rev Pharmacol Toxicol | 2007 | https://conductscience.org/library/papers/17067280 | PubMed |
| 8 | 9059598 | Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. | J Theor Biol | 1997 | https://conductscience.org/library/papers/9059598 | PubMed |
| 9 | 11698693 | Use of a stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development. | AIDS | 2001 | https://conductscience.org/library/papers/11698693 | PubMed |
| 10 | 16918905 | Hierarchical Bayesian methods for estimation of parameters in a longitudinal HIV dynamic system. | Biometrics | 2006 | https://conductscience.org/library/papers/16918905 | PubMed |
| 11 | 17632539 | Pharmacometrics and the transition to model-based development. | Clin Pharmacol Ther | 2007 | https://conductscience.org/library/papers/17632539 | PubMed |
| 12 | 11264471 | Drug treatment effects on disease progression. | Annu Rev Pharmacol Toxicol | 2001 | https://conductscience.org/library/papers/11264471 | PubMed |
| 13 | 9192676 | Virus dynamics and drug therapy. | Proc Natl Acad Sci U S A | 1997 | https://conductscience.org/library/papers/9192676 | PubMed |
| 14 | 11905835 | Modelling viral and immune system dynamics. | Nat Rev Immunol | 2002 | https://conductscience.org/library/papers/11905835 | PubMed |
| 15 | 18333871 | A receptor theory-based semimechanistic PD model for the CCR5 noncompetitive antagonist maraviroc. | Br J Clin Pharmacol | 2008 | https://conductscience.org/library/papers/18333871 | PubMed |
| 16 | 16078133 | Bridging the pharmacokinetics and pharmacodynamics of UK-279,276 across healthy volunteers and stroke patients using a mechanistically based model for target-mediated disposition. | Pharm Res | 2005 | https://conductscience.org/library/papers/16078133 | PubMed |
| 17 | 9857349 | Viral and host factors in the prediction of response to interferon-alpha therapy in chronic hepatitis C after long-term follow-up. | J Viral Hepat | 1998 | https://conductscience.org/library/papers/9857349 | PubMed |
| 18 | 11462181 | Initial virological and immunologic response to highly active antiretroviral therapy predicts long-term clinical outcome. | Clin Infect Dis | 2001 | https://conductscience.org/library/papers/11462181 | PubMed |
| 19 | 16849193 | Adherence to antiretroviral therapy and its impact on clinical outcome in HIV-infected patients. | J R Soc Interface | 2005 | https://conductscience.org/library/papers/16849193 | PubMed |
| 20 | 17515923 | Top-down versus bottom-up-rediscovering physiology via systems biology? | Mol Syst Biol | 2007 | https://conductscience.org/library/papers/17515923 | PubMed |
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42572208 | Viral Dynamic Model-Informed Dose Selection of Mosnodenvir Prophylaxis against DENV-3 in a Controlled Human Infection Model. | Clin Pharmacol Ther | 2026 | https://conductscience.org/library/papers/42572208 | PubMed |
| 36182824 | Accelerating model-informed decisions for COVID-19 vaccine candidates using a model-based meta-analysis approach. | EBioMedicine | 2022 | https://conductscience.org/library/papers/36182824 | PubMed |
| 34620860 | SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques. | Nat Commun | 2021 | https://conductscience.org/library/papers/34620860 | PubMed |
| 32144791 | Model-based meta-analysis of individual International Prostate Symptom Score trajectories in patients with benign prostatic hyperplasia with moderate or severe symptoms. | Br J Clin Pharmacol | 2020 | https://conductscience.org/library/papers/32144791 | PubMed |
| 28550375 | Exploring inductive linearization for pharmacokinetic-pharmacodynamic systems of nonlinear ordinary differential equations. | J Pharmacokinet Pharmacodyn | 2018 | https://conductscience.org/library/papers/28550375 | PubMed |
| 25288257 | Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop. | J Pharmacokinet Pharmacodyn | 2014 | https://conductscience.org/library/papers/25288257 | PubMed |
| 23945605 | Assessment of Maraviroc Exposure-Response Relationship at 48 Weeks in Treatment-Experienced HIV-1-Infected Patients in the MOTIVATE Studies. | CPT Pharmacometrics Syst Pharmacol | 2013 | https://conductscience.org/library/papers/23945605 | PubMed |
| 23933716 | On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach. | J Pharmacokinet Pharmacodyn | 2013 | https://conductscience.org/library/papers/23933716 | PubMed |
| 23713816 | Clinical pharmacology = disease progression + drug action. | Br J Clin Pharmacol | 2015 | https://conductscience.org/library/papers/23713816 | PubMed |
| 22773164 | From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part II: application to drug development. | J Pharmacokinet Pharmacodyn | 2012 | https://conductscience.org/library/papers/22773164 | PubMed |
| 22736302 | From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework. | J Pharmacokinet Pharmacodyn | 2012 | https://conductscience.org/library/papers/22736302 | PubMed |
| 21253559 | A novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen design. | PLoS Comput Biol | 2011 | https://conductscience.org/library/papers/21253559 | PubMed |
| 21088872 | The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects. | J Pharmacokinet Pharmacodyn | 2011 | https://conductscience.org/library/papers/21088872 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20204473
GET https://conductscience.org/api/papers/v1/20204473/references?page=2